Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer

Stopped early · Phase 2

Conditions studied: Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer

In brief

This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Key facts

Study ID

NCT00126568

Run by

National Cancer Institute (NCI)

People needed

20

Starts

2005-06-01

Expected to finish

2011-09-01

Last updated by the study team

2018-01-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Case Western Reserve University — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.